The Efficacy of a DNA Vaccine Encoding Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein D in Decreasing Ocular Disease Severity Following Corneal HSV-1 ChallengeArchives of Virology
AbstractAntiviral effects of a DNA vaccine against herpes simplex virus 1 (HSV-1) glycoprotein D (gD) were evaluated in eight week-old female BALB/c mice. The nuclease-insensitive construct (gD-ASOR) consisted of an HSV-1 gD encoding plasmid coupled to asialo orosomucoid (ASOR), targeting it to cells bearing ASOR receptors. Mice were immunized on day 0 and 7 with 10 μg doses of gD-ASOR or control substances. Fourteen days later, mice were infected by the corneal route with 105 pfu or 106 pfu HSV-1, strain 17syn+. Immunized mice showed a significant decrease in ocular disease severity over a 21-day observation period following infection compared to sham-immunized mice. Acute replication kinetic assays demonstrated a 100-fold decrease in viral titers on day 6 in trigeminal ganglia from immunized BALB/c mice compared to sham-immunized mice. Immunized mice showed a significant increase in numbers of CD4+T cells infiltrating the trigeminal ganglia at day 6 post infection compared to sham-immunized mice. Significant differences were not seen in latent viral reservoir between immunized and unimmunized mouse groups. Immunization with gD-ASOR decreased the severity of acute ocular HSV-1 infection, induced a CD4+ T cell response, decreased the viral load in the trigeminal ganglia, but did not diminish viral latency.
Citation InformationT. D. Frye, H. C. Chiou, Barbara E. Hull and Nancy J. Bigley. "The Efficacy of a DNA Vaccine Encoding Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein D in Decreasing Ocular Disease Severity Following Corneal HSV-1 Challenge" Archives of Virology Vol. 147 Iss. 9 (2002) p. 1747 - 1759 ISSN: 0304-8608
Available at: http://works.bepress.com/nancy_bigley/55/